Project Grant R01HL182042
Award Date 8/1/25
Completion Date 6/30/29
Dollars Obligated $865K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $267,000.00 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) for a project titled "Multimodal Characterization of Cardiac-Neurodevelopmental Genes." The project aims to (1) identify mechanisms by which certain genetic syndromes lead to alterations in both heart and brain development,...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $833,594 to investigate the pro-regenerative potential of the Pontin gene in the heart. The research aims to decipher the gene regulatory networks controlling cardiomyocyte (heart muscle cell) proliferation, with the goal of identifying druggable pathways to stimulate heart regeneration as a remedy for myocardial infarction....
- This federal Project Grant award, worth $809,162.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, located in Massachusetts. The funding supports research to elucidate the differentiation pathways and functions of pulmonary ionocytes, a rare cell type in the human airway that expresses high levels of the cystic fibrosis transmembrane...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $134,998 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes in San Francisco, CA. The grant, awarded on July 20, 2025, will support research to define the cellular and molecular mechanisms driving the formation of the linear heart tube during embryonic development. The primary objectives are to: 1) quantitatively analyze cell movements and behaviors required for proper...
- This Project Grant award, in the amount of $746,800.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at Baylor College of Medicine to investigate the major signaling mechanism controlling spontaneous cardiomyocyte (heart cell) proliferation in the neonatal stage. The research aims to elucidate the role of the CD36 receptor in regulating heart cell regeneration, with a...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $540,856 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Regents of the University of California, San Francisco (UCSF) on Dec 15, 2024. The goal of this 4-year project is to identify transcriptional regulators that control endocardial-specific gene expression and valve development, as well as understand the regulation and function of the SLC16A2 gene during heart injury and regeneration. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $279,644 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to study "Time to ROSC as a Novel Outcome for Pediatric Cardiac Arrest Trials." The project aims to develop new trial design techniques to enhance the feasibility of conducting high-quality randomized controlled trials for interventions to improve...
- This $802,762 federal Project Grant was awarded on February 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to interpret the impact of genetic variants, both coding and non-coding, on the development of congenital heart disease (CHD) by defining cardiac gene regulatory networks. The research aims to characterize the functions of variants in...